Counteracting the Mechanisms of Heart Failure is the Most Effective Way to Decongest Patients while Improving Outcomes
Cardiac failure review,
Год журнала:
2025,
Номер
11
Опубликована: Фев. 4, 2025
Diuretic
therapy
is
not
associated
with
improved
outcomes
in
heart
failure
and
may
cause
significant
side
effects.
Counteracting
the
core
pathophysiological
mechanisms
of
through
neurohormonal
blockade
while
reducing
reliance
on
diuretics
potentially
most
effective
method
decongestion.
Язык: Английский
Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis
Beth A. Davison,
Antonio Abbate,
Gad Cotter
и другие.
Heart Failure Reviews,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 12, 2025
Язык: Английский
Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial
ESC Heart Failure,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 11, 2025
Abstract
Aims
Patients
hospitalized
with
acute
heart
failure
(AHF)
treated
a
7
day
prednisone
course
in
the
CORTAHF
pilot
trial
had
greater
improvement
health‐related
quality
of
life
(QoL)
at
Day
both
overall
population
and
patients
baseline
interleukin
6
>
13
pg/mL.
This
post‐hoc
analysis
examines
specific
QoL
domains
relationship
between
clinical
signs
congestion
QoL.
Methods
In
trial,
AHF
high‐sensitivity
C‐reactive
protein
(hsCRP)
20
mg/L
were
randomized
1:1
to
once‐daily
oral
40
mg
for
days
plus
usual
care
or
alone.
completed
EQ‐5D‐5L,
including
EQ‐VAS,
Days
31.
We
estimated
baseline‐adjusted
treatment
effects
on
each
five
dimensions
evaluated
interaction
EQ‐VAS
effect
hsCRP
change
(the
primary
endpoint).
The
correlation
changes
evaluated.
Results
Among
100
patients,
was
driven
by
significant
EQ‐5D‐5L
mobility
[win
odds
1.48,
95%
confidence
interval
(CI)
1.05–2.12]
activities
(win
1.50,
CI
1.05–2.20)
domains.
independent
(interaction
P
=
0.13).
Decongestion
correlated
(
r
−0.528,
<
0.0001).
Conclusions
high
levels,
burst
steroid
therapy
improved
mostly
affecting
decongestion
may
therefore
not
be
direct
therapy,
but
mediated
through
HF
symptoms
signs.
Inflammatory
activation
reduced
irrespective
EQ‐VAS.
Язык: Английский
Can't Rain on Our Parade: Highlights from the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024
Journal of Cardiac Failure,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 1, 2024
In
the
STEP-HFpEF
trial,
semaglutide
was
shown
to
improve
HF-related
health
status
and
exercise
function
reduce
body
weight
(BW)
in
patients
with
obesity-related
HFpEF1.
The
first
prespecified
analysis
presented
explored
efficacy
safety
of
HFpEF
according
frailty
status1.
Results
showed
no
difference
loss
across
strata
(-6.8%
vs.
-8.0
vs
-8.8%
change
BW
increasing
status,
p=0.38).
However,
measured
by
Kansas
City
Cardiomyopathy
Questionnaire-12
Clinical
Summary
Score
(KCCQ-CSS)
did
vary
at
52
weeks
greatest
improvement
seen
among
most
frail
participants
(p=0.03).
A
second
investigated
effects
on
endpoints
range
impairment
baseline
6-minute
walk
distance
(6MWD).
Overall,
there
were
differential
effect
(reduced
BW,
improved
6MWD,
decreased
CRP
NT-proBNP)
spectrum
6MWD
(i.e.,
consistent
benefit).
Women
severe
(lowest
tertile)
appeared
derive
health-related
QOL
benefit
as
KCCQ-CSS
(mean
13.2
4.6
points
respectively
for
tertile
6MWD;
interaction
p=0.028).
Data
demonstrate
benefits
improving
symptoms
physical
limitations
even
a
high-risk
population.
Язык: Английский